Centessa Pharmaceuticals plc (NASDAQ:CNTA) Shares Bought by Farallon Capital Management LLC

Farallon Capital Management LLC lifted its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 24.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,498,709 shares of the company's stock after acquiring an additional 684,391 shares during the quarter. Farallon Capital Management LLC owned 2.65% of Centessa Pharmaceuticals worth $58,603,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. GAMMA Investing LLC boosted its holdings in Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock worth $64,000 after buying an additional 865 shares in the last quarter. Barclays PLC boosted its holdings in Centessa Pharmaceuticals by 1,414.9% during the fourth quarter. Barclays PLC now owns 5,302 shares of the company's stock worth $89,000 after buying an additional 4,952 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $162,000. China Universal Asset Management Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 39.1% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock worth $317,000 after buying an additional 5,316 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in Centessa Pharmaceuticals during the fourth quarter worth about $320,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Trading Down 0.8%

Shares of CNTA traded down $0.10 on Friday, hitting $12.29. 509,977 shares of the stock traded hands, compared to its average volume of 626,589. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $1.64 billion, a P/E ratio of -8.03 and a beta of 1.53. The stock's 50 day moving average is $13.86 and its two-hundred day moving average is $15.68. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.04. As a group, sell-side analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on CNTA shares. Piper Sandler started coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target on the stock. Morgan Stanley reaffirmed an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a report on Friday, March 7th. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a report on Thursday. They issued an "outperform" rating and a $6.00 price target on the stock. Guggenheim reaffirmed a "buy" rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Wednesday, March 26th. Finally, Chardan Capital started coverage on shares of Centessa Pharmaceuticals in a report on Thursday. They issued a "buy" rating and a $30.00 price target on the stock. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $27.00.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the transaction, the insider now owns 225,007 shares of the company's stock, valued at $3,863,370.19. This trade represents a 3.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the stock in a transaction that occurred on Thursday, February 20th. The stock was sold at an average price of $15.93, for a total transaction of $876,150.00. Following the transaction, the chief executive officer now directly owns 331,017 shares in the company, valued at approximately $5,273,100.81. This represents a 14.25% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 171,827 shares of company stock valued at $2,705,568. Company insiders own 11.59% of the company's stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.